$1.14
0.89% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US57055L1070
Symbol
MRKR

Marker Therapeutics, Inc. Stock price

$1.14
-0.06 5.00% 1M
-2.04 64.15% 6M
-1.97 63.34% YTD
-3.06 72.86% 1Y
-2.11 64.93% 3Y
-24.86 95.62% 5Y
-48.06 97.68% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.01 0.89%
ISIN
US57055L1070
Symbol
MRKR

Key metrics

Market capitalization $12.90m
Enterprise Value $-790.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.06
EV/Sales (TTM) EV/Sales -0.14
P/S ratio (TTM) P/S ratio 2.26
P/B ratio (TTM) P/B ratio 0.88
Revenue growth (TTM) Revenue growth 71.53%
Revenue (TTM) Revenue $5.70m
EBIT (operating result TTM) EBIT $-13.18m
Free Cash Flow (TTM) Free Cash Flow $-12.57m
Cash position $13.69m
EPS (TTM) EPS $-1.33
P/S forward 4.78
EV/Sales forward negative
Short interest 1.64%
Show more

Is Marker Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Marker Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Marker Therapeutics, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Marker Therapeutics, Inc. forecast:

Buy
100%

Financial data from Marker Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5.70 5.70
72% 72%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.85 4.85
14% 14%
85%
- Research and Development Expense 14 14
46% 46%
246%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
11% 11%
-231%
Net Profit -13 -13
11% 11%
-224%

In millions USD.

Don't miss a Thing! We will send you all news about Marker Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marker Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 16 hours ago
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase 1 APOLLO study expected later this year HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immun...
Neutral
GlobeNewsWire
one day ago
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025 Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025
Neutral
GlobeNewsWire
about 2 months ago
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons ...
More Marker Therapeutics, Inc. News

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Head office United States
CEO Juan Vera
Employees 5
Founded 1991
Website www.markertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today